Selank research, identity and evidence limits
Selank is a tuftsin-derived peptide with small human anxiety studies and preclinical mechanistic research. Those findings do not establish broad cognitive enhancement or comprehensive long-term safety.
Identity and formulation
The research molecule extends the tuftsin sequence with Pro-Gly-Pro. Modified derivatives or differently formulated products need their own evidence.
Selank and Semax are different molecules, despite similar names and overlapping marketing categories.
What the studies show
The literature should not be described as entirely preclinical: small patient comparisons exist. However, their limited reporting, active comparators and combination designs constrain the conclusions. Rodent neurotransmission studies address mechanism rather than demonstrating treatment benefit in people.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Selank compared with medazepam in anxiety and neurasthenia
Small comparative clinical study indexed as randomized Reading scope: PubMed abstract excerpt |
The abstract describes similar anxiolytic effects and additional reported symptom differences. | The retrieved abstract provides limited detail on masking and effect size; active-comparator similarity does not establish broad equivalence or long-term safety. |
| Selank added to phenazepam in anxiety disorders
Comparison of 30 monotherapy patients with 40 combination-treatment patients Reading scope: PubMed abstract |
The authors reported earlier changes on a symptom scale and fewer selected undesirable effects with the combination. | It does not isolate standalone Selank effects, and the abstract does not describe a blinded randomized allocation. |
| Selank and neurotransmission-related gene expression
Rat frontal-cortex gene-expression experiment Reading scope: Full-text methods and results sections |
Selank and GABA produced overlapping and differing changes in measured transcripts. | Transcript changes do not demonstrate receptor binding, patient benefit or freedom from dependence. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Claims such as non-addictive or free of withdrawal require appropriate follow-up, not simply comparison with a benzodiazepine in a small study.
Changes in neurotransmission-related gene expression can suggest mechanisms. They do not establish that a molecule behaves identically to GABA or treats every anxiety disorder.
Safety context
These studies do not characterize uncommon harms, long-term effects or all interactions. Findings from supervised combination treatment cannot validate unsupervised combinations or a different delivery route.
Study exposure and units
Keep the exact preparation and administration route attached to each study. Rodent intranasal exposure and clinical combinations cannot supply a generalized human injection or cognitive-enhancement regimen.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Confirm ordinary Selank sequence and any terminal modification. A report for tuftsin, Semax or a named modified Selank derivative does not establish ordinary Selank identity.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Are there human Selank studies?
Yes. The small comparisons summarized here are relevant, but are not a large, replicated, placebo-controlled evidence base for every promoted use.
Does the combination study show Selank works alone?
No. Both groups received phenazepam; the study examines adding Selank under its particular conditions.
Does a GABA-related result mean Selank is a benzodiazepine?
No. Shared downstream observations are not chemical identity or proof of an identical mechanism.
Sources
- Selank compared with medazepam in anxiety and neurasthenia (PubMed abstract excerpt)
- Selank added to phenazepam in anxiety disorders (PubMed abstract)
- Selank and neurotransmission-related gene expression (Full-text methods and results sections)